5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one | 97322-89-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
• 英文别名: [2-[[4-[(2-imino-4-oxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-5,7,8-trimethyl-3,4-dihydro-2H-chromen-6-yl] acetate
• CAS: 97322-89-9
• 化学式: C₂₅H₂₈N₂O₅S
• 分子量: 468.574
• InChiKey: MKRQOYXCBGLHSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one 在 盐酸 、 溶剂黄146 作用下， 以57%的产率得到5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-yl methoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022
• 作为产物：
  描述：

  [2-[(4-aminophenoxy)methyl]-5,7,8-trimethyl-3,4-dihydro-2H-chromen-6-yl] acetate 在 copper(I) oxide 、 盐酸 、 sodium nitrite 作用下， 以 环丁砜 为溶剂， 生成 5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022

文献信息

• Thiazolidine derivatives, their preparation and compositions containing
  申请人：Sankyo Company Limited

  公开号：US04572912A1

  公开（公告）日：1986-02-25

  The compounds of formula (I): ##STR1## [in which: R.sup.1 and R.sup.2 are the same or different and each represents hydrogen or C.sub.1 -C.sub.5 alkyl; R.sup.3 represents hydrogen, an acyl group, a (C.sub.1 -C.sub.6 alkoxy)carbonyl group or an aralkyloxycarbonyl group; R.sup.4 and R.sup.5 are the same or different and each represents hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.1 -C.sub.5 alkoxy, or R.sup.4 and R.sup.5 together represent a C.sub.1 14 C.sub.4 alkylenedioxy group; n is 1, 2 or 3; W represents the --CH.sub.2 --, >CO or >CH--OR.sup.6 group (in which R.sup.6 represents any one of the atoms or groups defined for R.sup.3 and may be the same as or different from R.sup.3); and Y and Z are the same or different and each represents oxygen or imino] and pharmaceutically acceptable salts thereof have various valuable therapeutic effects on the blood system and may be prepared by a process which includes reacting a corresponding halopropionic acid derivative with thiourea.

  化合物的化学式（I）：##STR1## [其中：R.sup.1和R.sup.2相同或不同，每个代表氢或C.sub.1 -C.sub.5烷基；R.sup.3代表氢，酰基，（C.sub.1 -C.sub.6烷氧）羰基或芳基氧羰基；R.sup.4和R.sup.5相同或不同，每个代表氢，C.sub.1 -C.sub.5烷基或C.sub.1 -C.sub.5烷氧，或R.sup.4和R.sup.5一起代表C.sub.1 14 C.sub.4烷二氧基基团；n为1、2或3；W代表--CH.sub.2 --，>CO或>CH--OR.sup.6基团（其中R.sup.6代表R.sup.3定义的任一原子或基团，可能与R.sup.3相同或不同）；Y和Z相同或不同，每个代表氧或亚胺]及其药学上可接受的盐对血液系统具有各种有价值的治疗效果，并可通过将相应的卤代丙酸衍生物与硫脲反应制备。
• Thiazolidine derivatives, their preparation and compositions containing them
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0139421B1

  公开（公告）日：1988-04-27
• YOSHIOKA, TAKAO;KITAZAWA, EIICI;KURUMADA, TOMOYUKI;YAMAZAKI, MITSUO;HASEG+
  作者：YOSHIOKA, TAKAO、KITAZAWA, EIICI、KURUMADA, TOMOYUKI、YAMAZAKI, MITSUO、HASEG+

  DOI：——

  日期：——
• US4572912A
  申请人：——

  公开号：US4572912A

  公开（公告）日：1986-02-25